Oligomerix Inc
June 06, 2024
Session
Company Description: Oligomerix initiated 1st in human clinical trials in January, 2023 for its lead tau inhibitor of self-association which works at the beginning of the tau cascade to prevent tau aggregation. Tau protein plays a key role in various dementias including Rare Diseases such as PSP (tauopathies) as well as in Alzheimer's. Our lead compound will provide an oral Tau-focused treatment with an outstanding safety profile that crosses the blood brain barrier as contrasted with most antibody programs. It has demonstrated efficacy in both therapeutic and prevention models in vivo. Oligomerix's oral small molecule formulation is a critical competitive advantage because it enables cost-effective, patient-centered treatment for the rapidly growing, unserved AD market in the context of significant and growing global healthcare system cost pressures..
